[Pharmacogenomic data for personalized medicines].
FDA issued guidance for industry regarding pharmarcogenomic data submission this year. Polymorphic cytochrome P450 2D6 and thiopurine S-methyltransferase in patients are now considered biomarkers for drugs which are predominantly metabolized by these enzymes. This article reviews current efforts to treat pharmacogenomic data for new drug development and personalized medicines.
Yamazaki
Hiroshi
H
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University.
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D014453:Glucuronosyltransferase / Q000235:genetics; D019983:Guideline Adherence; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics
D000970:Antineoplastic Agents; D019389:Cytochrome P-450 CYP2D6; D014453:Glucuronosyltransferase